Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial-Reference-Cited by-同舟云学术

Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial

Published:2023-01-02 Issue:1 Volume:19 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

López Pio¹,López-Medina Eduardo¹,Sáez-Llorens Xavier²³⁴,deAntonio Rodrigo²,Masuda Taisei⁵,Mendelman Paul M.⁶,Sherwood James⁵⁷,Baehner Frank⁵,Borkowski Astrid⁵⁷

Affiliation:

1. Department of Pediatrics, Centro de Estudios en Infectología Pediátrica S.A.S., Cali, Colombia

2. Department of Infectology, Cevaxin, The Panama Clinic, Panama City, Panama

3. Infectious Diseases, Hospital del Niño Dr. José Renán Esquivel, Panama City, Panama

4. Medicine (Pediatrics and Infectious Diseases), SNI, National Secretariat of Science, Technology and Innovation (SENACYT), Panama City, Panama

5. Clinical Development, Takeda Pharmaceuticals International AG, Zurich, Switzerland

6. Clinical Development, Takeda Vaccines Inc., Cambridge, MA, USA

7. Clinical Development, HilleVax GmbH, Glattpark-Zurich, Switzerland

Funder

funding

Publisher

Informa UK Limited